Department of Pathology, Hospital Clínic, IDIBAPS, University of Barcelona, Villarroel, 170, Barcelona 08036, Spain.
Br J Cancer. 2010 Aug 10;103(4):510-6. doi: 10.1038/sj.bjc.6605788. Epub 2010 Jul 27.
Mucoepidermoid carcinoma (MEC) shows differences in biological behaviour depending mainly on its histological grade. High-grade tumours usually have an aggressive biological course and they require additional oncological treatment after surgery.
In a series of 43 MECs of the salivary glands, we studied the epidermal growth factor receptor (EGFR) gene by using dual-colour chromogenic in situ hybridisation (CISH). Moreover, we assessed the protein expressions of the EGFR and the activated extracellular signal-regulated kinases (pERK1/2) by using immunohistochemistry. These results were correlated with the histological grade of the tumours and the outcome of the patients.
The CISH study demonstrated a high-EGFR gene copy number, with balanced chromosome 7 polysomy, in 8 out of 11 high-grade MECs (72.7%), whereas 27 low-grade and 15 intermediate-grade tumours had a normal EGFR gene copy number (P<0.001). The EGFR gene gains correlated with disease-free interval (P=0.003) and overall survival of the patients (P=0.019). The EGFR protein expression had a significant correlation with the histological grade of the tumours but not with the outcome of the patients. The pERK1/2 expression correlated with histological grade of tumours (P<0.001), disease-free interval (P=0.004) and overall survival (P=0.001).
The EGFR/ERK pathway is activated in high-grade MECs with aggressive behaviour. Patients with these tumours who require oncological treatment in addition to surgery could benefit from EGFR and mitogen-activated protein kinase pathway inhibitors.
黏液表皮样癌(MEC)的生物学行为存在差异,主要取决于其组织学分级。高级别肿瘤通常具有侵袭性的生物学行为,在手术后需要额外的肿瘤治疗。
在一组 43 例涎腺 MEC 中,我们使用双色显色原位杂交(CISH)研究了表皮生长因子受体(EGFR)基因。此外,我们还通过免疫组织化学评估了 EGFR 和激活的细胞外信号调节激酶(pERK1/2)的蛋白表达。这些结果与肿瘤的组织学分级和患者的预后相关。
CISH 研究显示,11 例高级别 MEC 中有 8 例(72.7%)存在高 EGFR 基因拷贝数和平衡的染色体 7 三体,而 27 例低级别和 15 例中级别肿瘤具有正常的 EGFR 基因拷贝数(P<0.001)。EGFR 基因获得与无病间期(P=0.003)和患者总生存期(P=0.019)相关。EGFR 蛋白表达与肿瘤的组织学分级有显著相关性,但与患者的预后无关。pERK1/2 的表达与肿瘤的组织学分级相关(P<0.001),与无病间期(P=0.004)和总生存期(P=0.001)相关。
具有侵袭性行为的高级别 MEC 中 EGFR/ERK 通路被激活。这些肿瘤患者在手术后需要额外的肿瘤治疗,可能受益于 EGFR 和丝裂原活化蛋白激酶途径抑制剂。